{"id":198857,"date":"2025-09-07T12:20:14","date_gmt":"2025-09-07T12:20:14","guid":{"rendered":"https:\/\/www.premium-partners.net\/?p=198857"},"modified":"2025-09-08T04:18:04","modified_gmt":"2025-09-08T04:18:04","slug":"who-adds-ozempic-and-mounjaro-to-its-list-of-essential-medicines","status":"publish","type":"post","link":"https:\/\/www.premium-partners.net\/fr\/builder\/who-adds-ozempic-and-mounjaro-to-its-list-of-essential-medicines\/","title":{"rendered":"WHO adds Ozempic and Mounjaro to its list of essential medicines"},"content":{"rendered":"<p>This <a target='_blank' rel=\"nofollow\" href=\"https:\/\/www.iol.co.za\/business-report\/international\/who-adds-ozempic-and-mounjaro-to-its-list-of-essential-medicines-b926ef36-79fc-47db-bbb0-abd059930b64\">post<\/a> was originally published on <a target='_blank' rel=\"nofollow\" href=\"https:\/\/www.iol.co.za\/\">this site<\/a><\/p><p><img decoding=\"async\" src=\"https:\/\/image-prod.iol.co.za\/16x9\/800?source=https:\/\/iol-prod.appspot.com\/image\/8b62dbddce9e12bd8dcf383b2cc3e2282a9afbb9\/2321&amp;operation=CROP&amp;offset=0x121&amp;resize=2321x1306\" class=\"type:primaryImage\" \/><\/p>\n<p>The World Health OrganiSation added Novo Nordisk\u2019s Ozempic and Eli Lilly &amp; Co.\u2019s Mounjaro to its list of essential medicines, a step that may expand access to the drugs around the world.<\/p>\n<p>The recommendation applies to a range of GLP-1 drugs that also includes Lilly\u2019s older medicine Trulicity and Novo\u2019s Victoza, the WHO said on Friday.<\/p>\n<p>The public health agency didn\u2019t say it\u2019s essential to take GLP-1s for obesity as a standalone condition, instead focusing on their use for diabetes patients who also have heart or kidney disease as well as obesity. That\u2019s because the strongest evidence that the drugs help patients is in people who have several cardiometabolic conditions, said Lorenzo Moja, a scientist in the WHO secretariat of the model list of essential medicines.<\/p>\n<p>\u201cWhere resources allow, countries should consider expanding access programs,\u201d Moja said by email. The WHO said generic competition should be encouraged to drive down the price of the drugs and make them more available in day-to-day health care.<\/p>\n<p>The WHO updates its list of essential medicines every two years. More than 800 million people in the world have diabetes, the WHO said, while more than 1 billion people have obesity.<\/p>\n<p><strong>BLOOMBERG<\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>The World Health OrganiSation added Novo Nordisk\u2019s Ozempic and Eli Lilly &amp; Co.\u2019s Mounjaro to its list of essential medicines, a step that may expand access to the drugs around the world.The recommendation applies to a range of GLP-1 drugs that also includes Lilly\u2019s older medicine Trulicity and Novo\u2019s Victoza, the WHO said on Friday.The public health agency didn\u2019t say it\u2019s essential to take GLP-1s for obesity as a standalone condition, instead focusing on their use for diabetes patients who also have heart or kidney disease as well as obesity. That\u2019s because the strongest evidence that the drugs help patients is in people who have several cardiometabolic conditions, said Lorenzo Moja, a scientist in the WHO secretariat of the model list of essential medicines.\u201cWhere resources allow, countries should consider expanding access programs,\u201d Moja said by email. The WHO said generic competition should be encouraged to drive down the price of the drugs and make them more available in day-to-day health care.The WHO updates its list of essential medicines every two years. More than 800 million people in the world have diabetes, the WHO said, while more than 1 billion people have obesity.BLOOMBERG<\/p>","protected":false},"author":1,"featured_media":198859,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-198857","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-builder"],"_links":{"self":[{"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/posts\/198857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/comments?post=198857"}],"version-history":[{"count":2,"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/posts\/198857\/revisions"}],"predecessor-version":[{"id":198860,"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/posts\/198857\/revisions\/198860"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/media\/198859"}],"wp:attachment":[{"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/media?parent=198857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/categories?post=198857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.premium-partners.net\/fr\/wp-json\/wp\/v2\/tags?post=198857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}